Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (September 2023)
31 slides from Windtree Therapeutics's investor presentation, Sep 26, 2023
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics ‘ Company Overview September 2023 ee —@ WINDTREE (NASDAQ: WINT)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's
Slide 3: Investment Highlights
Investment Highlights WINDTREE THERAPEUTICS V/ Clinical stage biopharmaceutical company focused on acute cardiovascular critical conditions with advanced stage programs intended to address large markets with significant unmet needs (NASDAQ: WINT) First in class, novel lead asset istaroxime has demon
Slide 4: Multi-Asset / Indication Pipeline with Several Near-Term Milestones
Multi-Asset / Indication Pipeline with Several Near-Term Milestones Cardiogenic Shock with Istaroxime as Lead Program Pronty Program Istaroxime Cardiogenic Shock Muti-asset fone —)— (tstaroxime ‘Acute Heart Failure (cea partnership OralSERCAZa Chronic Heart Failue, inciuding echnical Activators Pote
Slide 5: Istaroxime Milestones and Strategy for Value Creation
Istaroxime Milestones and Strategy for Value Creation 2023 2024 2025 Q3 Q4 Qi Q2 Q3 Q4 FDA @ istsronime carsiogenic'shock —He-cm Phase2 exeseeh — MM Cardiogenic Shock SBME a Ss © csc Dp + Completedand ra Positive Results Istaroxime in Acute Heart Failure pote bea ae Failure Study*** Augment Cardogen
Slide 6: Istaroxime Cardiogenic Shock
by So —“ Istaroxime Cardiogenic Shock Potential to transform the standard of care for critical patients
Slide 7: Cardiogenic Shock - A Critical Condition Caused by a Failing Heart
Cardiogenic Shock - A Critical Condition Caused by a Failing Heart A severe presentation of heart failure characterized by low blood pressure and inadequate blood flow to vital organs (hypoperfusion) accompanied by congestion and high filling pressures of the heart. It requires very urgent treatment
Slide 8: Significant Unmet Need and Reported Desire for Istaroxime
Significant Unmet Need and Reported Desire for Istaroxime + No satisfactory pharmacological intervention to reverse the conditions Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and even increases in mortality that limit thei
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action eo Improves Cardiac Relaxation via stimulation of SERCAZA activity which enhances cealeium reuptake () Increases the Force of Cont
Slide 10: Istaroxime Cardiogenic Shock Program Came from AHF Phase Trials
Istaroxime Cardiogenic Shock Program Came from AHF Phase 2 Trials and the Potential Attractive Regulatory Pathway Phase 2a and 2b data in AHF - istaroxime uniquely and significantly improved: Cardiac Function + increased stroke volume + lowered cardiac filling pressures Systolic Blood Pressure Renal
Slide 11: SEISMiC Early Cardiogenic Shock Study
SEISMIC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure a ka se PY WINDTREE 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo
Slide 12: Istaroxime Achieved Positive Primary Endpoint
SN ie Istaroxime Achieved Positive Primary Endpoint Systolic Blood Pressure AUC through 6 Hours - mITT Population mt) Blstaroxime e) 3 B ‘Placebo 0 os is 225 3 35 4 48 S$ SS 6 & Hours from Infusion Inititation WINDTREE 2)
Slide 13: Secondary Results
\ Secondary Results Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population 20 ‘s —*Istaroxime 3 © Placebo 2 = & rs a é t t { p=0,025 for AUC 2 o 0 2 2 Hours from Infusion initiation ae WINDTREE cy
Slide 14: Cardiac Function Improvement
Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: ¥ Cardiac index (amount of output from the heart over a minute) significantly increased ¥ Stroke volume (amount of blood from the heart with each heartbeat) subs
Slide 15: Treatment was Associated with a Favorable Renal Profile
Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate miTT Population ‘change from Baseline in eGFR (mliminit.73m") oe Istaroxime S| =e Placebo Hours fromintusion initiation WINDTREE Data shonmas m
Slide 16: Comparison of Doses
\ Comparison of Doses 1.0 pg/kg/min Produced a Favorable Effect on SBP 1.0 g/kgimin dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function + More favorable adverse event, serious adverse event and clinical event profile 21.0
Slide 17: SEISMiC Study Results Summary
SEISMiC Study Results Summary v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapid within the first hour and sustained through the 96-hour p
Slide 18: Cardiogenic Shock Development Strategy
Cardiogenic Shock Development Strategy Focus on thoroughness, speed and relatively low cost of trials SEISMIC Extension Study * Extended and titrated dosing for optimization = Additional characterization SEISMIC trees ete — Cos of $4 1M Study ~8 months enrollment, data expected 0224 = Execute EOP2 m
Slide 19: Istaroxime Cardiogenic Shock Studies
Istaroxime Cardiogenic Shock Studies Expected Steps to Phase 3 Readiness Dose Optimization — Extension Study SCAI Stage C Study Study Objectives: Study Objectives: * Advance the characterization of the physiology * Gain experience with istaroxime in SCAI stage C patients associated with longer istar
Slide 20: Cardiogenic Shock Represents a Significant Opportunity for Istaroxime and Windtree
Cardiogenic Shock Represents a Significant Opportunity for Istaroxime and Windtree DRIVERS OF OPPORTUNITY AND COMMERCIAL VALUE ‘STRATEGIC POSITIONING Covers 85%" of Addressable Market? 1. Expand the Market due to Profile: Yo Very long average length of hospital stay VY. (19.5 days") means high cost
Slide 21: Istaroxime Acute Heart Failure
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure
Slide 22: Heart Failure — A Large and Growing Market with Significant Mortality and Unmet Need
Heart Failure — A Large and Growing Market with Significant Mortality and Unmet Need #1 cause of U.S. Annual Admissions Patients QS hospitalization ~1.3M us. 7us,, in patients a n > 65 years old 1.5M ev. 25M worawide ~7% (Sf) >$18B Glo In-patient mortality annual U.S. hospital costs New pharmacologi
Slide 23: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need tient Management Goals Current Treatment Options » Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary Heart rhythm disturbances
Slide 24: Istaroxime AHF Phase 2a & 2b Studies
Istaroxime AHF Phase 2a & 2b Studies se PY WINDTREE Phase , 2a n=120 Dosing= 6 hour ADHF Patients 0.5, 1, 1.5 ugikgimin Infusion Phase n=120 Dosing= 24 hour 2b ADHF Patients 0-5, 1.0 vokgimin Infusion (ayspnea pus need torIv turosemiae > 4omg) Primary: PCWP significantly improved Stroke Vol & SBP —
Slide 25: Istaroxime in AHF Phase 2b — Results Summary
Istaroxime in AHF Phase 2b — Results Summary Cardiac Function Improved with Both Doses 5 ie + Significant increase in stroke volume (amount of blood expelled with each heartbeat) + Lowered cardiac filling pressures aft Increased in Systolic Blood Pressure \ 1 eS Increased Renal Function (eGFR) Heart
Slide 26: Istaroxime — Acute Heart Failure
NES Istaroxime — Acute Heart Failure Objective: Evaluate potential Phase 3 AHF program based on data from our cardiogenic shock program Potential Phase 3 AHF Program ‘Augment our data from the positive phase 2a and phase 2b AHF studies oe with the efficacy, safety and dosing and characterization lea
Slide 27: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Nat/K+) Activators Compounds + Potential Oral & i.v. therapies for + “Next generation istaroxime’
Slide 28: Active Engagement in BD Opportunities
Active Engagement in BD Opportunities Goal: Non-Dilutive Resourcing and Creating Shareholder Value AEROSURF / KL4 Platform — + Exclusive global license to Lee's Pharm and Zhaoke. Potential proceeds: © Up to $78.9 million in potential milestone payments, low double-digit % royalties © WINT no longer
Slide 29: Milestones and Financial Summary
Milestones and Financial Summary Cash June 30, 2023 $11.6M Driving Capital Efficiency to Program Investment Significantly reduced company expenses and cash burn via out- licensing KL4 platform, focused resources on lead priority program Total Company Burn / Month Reduction 1H'22 vs. 1H'23 Non-Progra
Slide 30: Strategy for Value-Creation
Strategy for Value-Creation - Focus for the Next 4-6 Quarters Clinical Milestones of and SCAI + Enable transi Executes WINDTREE Transformative BD Licensing and partnership for non-dilutive value WINT Team Retention, Motivation and Performance Culture High IR/PR munication dedicated media, etc 0
Slide 31: Slide 31
Windtree Therapeutics — Investor Presentation (September 2023) on 6ix